	US 11,911,479 B2
	Vaginal hydrogel
Brenda K. Mann, Salt Lake City, UT (US)
Filed by Brenda K. Mann, Salt Lake City, UT (US)
Filed on Feb. 1, 2022, as Appl. No. 17/590,213.
Application 17/590,213 is a continuation of application No. 15/991,870, filed on May 29, 2018, granted, now 11,419,941.
Claims priority of provisional application 62/512,588, filed on May 30, 2017.
Prior Publication US 2022/0152209 A1, May 19, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/38 (2006.01); A61K 9/00 (2006.01); A61K 47/34 (2017.01); A61K 45/06 (2006.01); A61P 15/02 (2006.01); A61K 47/32 (2006.01); A61P 31/04 (2006.01); A61P 3/04 (2006.01); A61K 31/565 (2006.01)

CPC A61K 47/38 (2013.01) [A61K 9/0034 (2013.01); A61K 45/06 (2013.01); A61K 47/32 (2013.01); A61K 47/34 (2013.01); A61P 15/02 (2018.01); A61P 31/04 (2018.01); A61K 31/565 (2013.01)]

12 Claims

1. A method for making a crosslinked composition, the method comprising:

forming a mixture comprising:

a glycosaminoglycan comprising a plurality of thiol groups and having a thiol modification of about 0.1 to about 0.4 μmol thiol per mg of glycosaminoglycan, and

a molecule comprising poly(ethylene glycol) having at least two thiol-reactive sites, wherein the molar ratio of the thiol groups to the thiol reactive sites in the mixture is at least 2:1 ; and

crosslinking the glycosaminoglycan and the poly(ethylene glycol) at a pH between about 3.2 and about 5.0,

wherein the crosslinked composition comprises about 0.05 to about 0.2 μmol uncrosslinked thiol groups per mg of the glycosaminoglycan.